|
|
|
|
|
|
|
|
|
|
|
|
|
13.01.26 - 18:03
|
Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--#AstraZeneca--Modella AI, a leader in artificial intelligence for life sciences, today announced that it has been acquired by AstraZeneca, expanding the companies' existing collaboration to advance the application of multi-modal AI foundation models and AI agents across AstraZeneca's global oncology portfolio.
The acquisition follows a multi-year agreement with AstraZeneca announced in July 2025 and will integrate Modella AI's generative and agentic AI platform into AstraZeneca's oncology research and development organization, supporting efforts to accelerate clinical development, enhance biomarker discovery, and enable the next wave of data-driven decision-making across the pipeline.
“Oncology drug development is becoming more complex, more data-rich, and more time-sensitive, and our companies expect AI solutions that are not only powerful but truly deployable in global trials and clinical settings,” said Gabi Raia, Chief Commercial Officer of Modella AI. “By joining As...
|
|
|
|
|
12.01.26 - 21:54
|
Nvidia to Invest $1 Billion in AI Drug Lab With Eli Lilly (Bloomberg)
|
|
|
Nvidia plans to invest $1 billion over five years in a new laboratory with Eli Lilly & Co., in an effort to speed up the use of AI in the pharmaceutical industry. Denny Fish, portfolio manager on the Global Technology and Innovation Team at Janus Henderson Investors, joins Caroline Hyde and Ed Ludlow on “Bloomberg Tech.” (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.01.26 - 14:48
|
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASC (GlobeNewswire EN)
|
|
|
CHICAGO and FORT WORTH, Texas, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that new additional and promising patient survival and biomarker data from treatment with elraglusib for metastatic pancreatic cancer were featured in oral and poster presentations at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 9, 2026. The presentations highlighted new, expanded data from the Company's Phase 2 clinical program (Actuate 1801-Part 3B) evaluating elraglusib in combination with gemcitabine/nab-paclitaxel (GnP), a first-line chemotherapy regimen for metastatic pancreatic cancer, providing additional evidence that suggests that elraglusib combined with GnP is associated wi...
|
|
|
|
|
12.01.26 - 13:06
|
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update (Business Wire)
|
|
|
Preliminary full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million
Novocure to present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PST on Wednesday, January 14, 2026BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
“Novocure exits 2025 having achieved record annual revenue, providing the financial strength to execute on the exciting growth opportunities we have in 2026,” said Frank Leonard, CEO, Novocure. “We have built the team and capabilities to support multiple product launches in the coming year while ensuring the company is on a clear path to profitability.”
Financial updates for the year and fourth ...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
